Verisante Technology Inc.

C$0.01As of Sun 8 Nov 2026, 12:00 UTC
TSXV:VER-HHealthcare
Country Canada
PE (Fwd) —
TSR 10Y CAGR (27.47%)
Div yield —
ROE —
Medical Devices
Beta (5Y) 47.60
PE TTM 14.06
TSR TTM —
Mkt cap C$0.439M
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
$0.0108
7.80%
54.60%
Price below Reference Value
2Q25
4Q25
1Q26
2Q26
Earnings per share$
—
—
—
—
—
—
—
—
Revenue$M
—
—
—
—
—
—
—
—
TTM
FYE 31 Dec CAD
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026E
Trend
5Y
10Y
Peers
◌—
Revenue$M
—
—
—
—
—
—
◌—
◌—
◌—
◌—
—
—
—
—
—
Revenue growth%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Gross margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Operating margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Net margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
14.06
P/E ratio (avg)x
—
—
—
—
—
—
0.365
—
—
18.21
—
9.288
—
—
—
EV/EBITx
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(7.47)
FCF yield (avg)%
—
—
—
—
—
—
(41.19)
(16.95)
(3.66)
(5.77)
—
(11.36)
—
64
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(1.050)
FCF / Net incomex
—
—
—
—
—
—
(0.150)
1.223
0.244
(1.050)
—
0.047
—
—
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
633.16
Return on assets%
—
—
—
—
—
—
1360.37
(253.37)
(975.50)
633.16
—
189.90
—
4
—
EPS$
—
—
—
—
—
—
0.07
—
—
—
—
(78.62%)
—
—
126.52
EPS growth%
—
—
—
—
—
—
—
(103.65)
(0.91)
126.52
—
(0.91)
—
—
—
Bookvalue per sh$
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share$
—
—
—
—
—
—
(0.01)
—
—
—
—
—
—
—
—
Dividend per sh$
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Div yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Payout ratio%
—
—
—
—
—
—
—
—
—
—
—
—
—
—
43.94
Shares (diluted)M
—
—
—
—
—
—
◇16.51
34.07
42.81
43.94
◌43.94
38.58%
—
89
(2.65)
Buyback yield%
—
—
—
—
—
—
—
(106.37)
(25.63)
(2.65)
◌—
(25.63)
—
89
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.439
Enterprise value$M
—
—
—
—
—
—
0.353
0.623
0.757
0.568
0.439
17.24%
—
0
—
LT debt$M
—
—
—
—
—
—
—
—
—
—
—
—
—
33
Peers (US$0.091M)
Cap (US$)
PE
0.112M
—
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
—
—
—
Own earn%
—
—
—
Sh yield%
(2.65)
(25.63)
(25.63)
Owners
Insiders/Inst%
75.14
—
Short interest%
—
SBC / revenue%
—
Record
10Y
Profitable years
2/4
Revenue growth years
—
EPS growth years
1/3
Dividend streakyrs
0
Op margin range%
—
$1 testx
—
Incr. ROIC%
—

Verisante Technology Inc. does not have significant operations. Previously, it was involved in the design and manufacture of cancer diagnostic devices. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. Verisante Technology Inc. was incorporated in 2006 and is based in Vancouver, Canada.

Revenue by segment
No breakdown available
Asset mix
Share
Trend
Other
84.94%
Cash and investments
15.06%
Reinvestment returns
No breakdown available